Diabetic Medicine

The current and future roles of the consultant diabetologist
pp. 929-930(2)
Author: Holt, Richard I. G.

Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?
pp. 931-933(3)
Author: Bilous, R. W.

The importance of free fatty acids in the development of Type 2 diabetes
pp. 934-945(12)
Author: Wilding, J. P. H.

A review of the job satisfaction and current practice of consultant diabetologists in England—barriers and successes
pp. 946-954(9)
Authors: MacLeod, K.; Carter, M.; Asprey, A.; Britten, N.; Dean, J.; Hillson, R.; Mackie, A.; Morrish, N.

Comparison between vildagliptin and metformin to sustain reductions in HbA_1c over 1 year in drug-naïve patients with Type 2 diabetes
pp. 955-961(7)
Authors: Schweizer, A.; Couturier, A.; Foley, J. E.; Dejager, S.

Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes
pp. 962-968(7)
Authors: Aso, Y.; Yamamoto, R.; Suetsugu, M.; Matsumoto, S.; Wakabayashi, S.; Matsutomo, R.; Takebayashi, K.; Inukai, T.

Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes
pp. 969-976(8)
Authors: Spijkerman, A. M. W.; Gall, M.-A.; Tarnow, L.; Twisk, J. W. R.; Lauritzen, E.; Lund-Andersen, H.; Emeis, J.; Parving, H.-H.; Stehouwer, C. D. A.

The association between baseline characteristics and the outcome of foot lesions in a UK population with diabetes
pp. 977-981(5)
Authors: Ince, P.; Kendrick, D.; Game, F.; Jeffcoate, W.

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK
pp. 982-1002(21)
Authors: Valentine, W. J.; Bottomley, J. M.; Palmer, A. J.; Brändle, M.; Foos, V.; Williams, R.; Dormandy, J. A.; Yates, J.; Tan, M. H.; Massi-Benedetti, M.

Prognostic significance of asymptomatic coronary artery disease in patients with diabetes and need for early revascularization therapy
pp. 1003-1011(9)
Authors: Choi, E.-K.; Koo, B.-K.; Kim, H.-S.; Cho, Y.-M.; Kang, H.-J.; Cho, Y.-S.; Chung, W.-Y.; Chae, I.-H.; Choi, D.-J.; Oh, B.-H.; Park, Y.-B.; Choi, Y.-S.

Evidence for distinct effects of GH and IGF-I in the metabolic syndrome
pp. 1012-1018(7)
Authors: Maison, P.; Balkau, B.; Souberbielle, J.-C.; Cunin, P.; Vol, S.; Macquin-Mavier, I.; Eschwège, E.

Effects of structured hospital-based care compared with standard care for Type 2 diabetes—The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial
pp. 1019-1027(9)
Authors: Johansen, O. E.; Gullestad, L.; Blaasaas, K. G.; Orvik, E.; Birkeland, K. I.

Child and parental personality are associated with glycaemic control in Type 1 diabetes
pp. 1028-1033(6)
Authors: Vollrath, M. E.; Landolt, M. A.; Gnehm, H. E.; Laimbacher, J.; Sennhauser, Felix H.

The effect of α-lipoic acid on symptoms and skin blood flow in diabetic neuropathy
pp. 1034-1038(5)
Authors: Jin, H. Y.; Joung, S. J.; Park, J. H.; Baek, H. S.; Park, T. S.

Plasma endothelin response to acute hypoglycaemia in adults with Type 1 diabetes
pp. 1039-1042(4)
Authors: Wright, R. J.; Macleod, K. M.; Perros, P.; Johnston, N.; Webb, D. J.; Frier, B. M.

Increased sickness absence in diabetic employees: what is the role of co-morbid conditions?
pp. 1043-1048(6)
Authors: Kivimäki, M.; Vahtera, J.; Pentti, J.; Virtanen, M.; Elovainio, M.; Hemingway, H.

The intake of potatoes and glucose metabolism in subjects at high risk for Type 2 diabetes
pp. 1049-1050(2)
Authors: Ylönen, S. K.; Virtanen, S. M.; Groop, L.

Hyperglucagonaemia is not a primary metabolic defect in non-diabetic first-degree relatives from Type 2 diabetic families
pp. 1050-1051(2)
Authors: Jayapaul, M. K.; Walker, M.

The diagnosis of diabetes
pp. 1051-1052(2)

Diary dates
pp. 1053-1053(1)

Corrigendum
pp. 1054-1054(1)